Last reviewed · How we verify
Leptin
At a glance
| Generic name | Leptin |
|---|---|
| Also known as | no other names, Metreleptin, Recombinant-methionyl Human Leptin., r-metHuLeptin, A-100 |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy (PHASE2)
- Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy (PHASE3)
- Physical Exercise and Biomolecular Analysis to Reduce Uremic Toxins in Chronic Kidney Disease: An Exploratory Study (NA)
- Adipokines in Polycystic Ovary Syndrome
- The Influence of Non-Caloric Artificial Sweeteners on Youth With Type 1 Diabetes
- Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling
- A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults (PHASE3)
- Effect of a Low-Calorie MCT-Rich Traditional Minangkabau Diet on Obese Individuals (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Leptin CI brief — competitive landscape report
- Leptin updates RSS · CI watch RSS
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) portfolio CI